StocksTelegraph
S&P 500—NASDAQ—DOW—RUSSELL—
NASDAQ · ZYBT·Healthcare

Zhengye Biotechnology Holding Limited Stock Analysis & AI Score

Zhengye Biotechnology Holding Limited (ZYBT) has an ST Score of 28.8 (C-), driven by its Momentum (B-) and held back by its Growth (F). ZYBT last traded at $1.31.

Market Closed
$1.31
Prev Close
—
Market Cap
—
Day Range
—
52W Range
—
P/E
—
EPS (TTM)
—
Volume
—
Avg —
Beta
—
29
ST Score
28.8/100C-

Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.

As of
AI Daily Briefing
Analysis by AI
Price History
—
Technical Indicators
FMP
Earnings Surprises
Analyst Forecast
Revenue Mix

Company Information

Employees—
CEO—
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date—
Website—
Country—
ExchangeNASDAQ

SEC Filings

Annual Report (10-K)

Filing DateAcceptedLink
Loading…

Quarterly Report (10-Q)

Filing DateAcceptedLink
Loading…
Analyst Price Target
ESG Score
Latest News

ST Score

ZYBT
28.8out of 100
Grade C-

Zhengye Biotechnology Holding Limited (ZYBT) has an ST Score of 28.8 (C-), driven by its Momentum (B-) and held back by its Growth (F). ZYBT last traded at $1.31.

Strongest
MomentumB-
Weakest
GrowthF
All factor grades
  • MomentumB-
  • ValuationC+
  • Financial StrengthC
  • ProfitabilityF
  • GrowthF
Score methodology
Press Releases

Contact

ZYBT stock: frequently asked questions

What is ZYBT's ST Score?

Zhengye Biotechnology Holding Limited (ZYBT) has an ST Score of 28.8 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Is ZYBT a buy, hold, or sell?

Our ST Score grades it C- (28.8/100). The ST Score is a data-driven signal, not a recommendation.

What are ZYBT's factor grades?

Valuation C+, Profitability F, Financial Strength C, Momentum B-, Growth F.

What is ZYBT's valuation grade?

Zhengye Biotechnology Holding Limited (ZYBT) earns a valuation grade of C+, measured against Drug Manufacturers - Specialty & Generic peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

What is ZYBT's growth grade?

Zhengye Biotechnology Holding Limited (ZYBT) earns a growth grade of F, measured against Drug Manufacturers - Specialty & Generic peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

What is ZYBT's profitability grade?

Zhengye Biotechnology Holding Limited (ZYBT) earns a profitability grade of F, measured against Drug Manufacturers - Specialty & Generic peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

What is ZYBT's financial strength grade?

Zhengye Biotechnology Holding Limited (ZYBT) earns a financial strength grade of C, measured against Drug Manufacturers - Specialty & Generic peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.